Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · GYRE THERAPEUTICS, INC. (GYRE)

Gyre Therapeutics Q3 revenue rises 1% to $32.9 million; net loss of $2.5 million

Mixed Impact 3 of 5 earnings Written later

Gyre Therapeutics reported third-quarter 2026 revenue of $32.9 million, up 1% from $32.7 million a year earlier, but swung to a net loss of $2.5 million from net income of $1.9 million. The company affirmed its full-year 2026 revenue guidance of $100.5 million to $111.0 million, while nine-month results showed a larger loss and lower revenue, which matters to shareholders weighing the cost of the Cullgen acquisition and clinical spending.

Key points

  • Q3 2026 revenue was $32.9 million versus $32.7 million in Q3 2025; ETUARY sales were $31.4 million.
  • Q3 GAAP basic EPS was $(0.04), compared with $0.01 a year earlier.
  • Nine-month net loss was $35.3 million versus net income of $4.6 million; nine-month revenue was $86.5 million versus $93.0 million.
  • Total cash, deposits and certificates of deposit were $98.8 million at September 30, 2026, down from $116.1 million at December 31, 2025.

The filing

CompanyGYRE THERAPEUTICS, INC. (GYRE)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:30 PM ET
Accession number0001193125-26-449985

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.